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1. INTRODUCTION
Cardiovascular (CV) diseases are the leading causes of morbid-
ity and mortality in industrialized countries worldwide, despite 
the availability of highly effective preventive treatments. This 
phenomenon is even more pronounced in chronic kidney dis-
ease (CKD), especially in end-stage renal disease (ESRD), as CV 
mortality of patients on maintenance hemodialysis (HD) is more 
than 10-fold higher compared with the normal population [1]. 
Therefore, attempts in ESRD to better identify high risk patients 
and their more effective prevention have an outmost importance.
In the past two decades numerous investigations demonstrated 
that aortic stiffening as measured by carotid-femoral Pulse Wave 
Velocity (PWV) predicts mortality independently of traditional risk 
factors. The most striking effect was observed in ESRD patients on 
maintenance HD, in whom a 3.4 m/s increase in PWV was associ-
ated with a threefold rise in the risk for mortality [2]. Based on the 
accumulating evidence regarding the role of PWV in the prediction 
of target organ damage, PWV was assigned as IIa recommendation 
in the European hypertension guidelines in 2007 and 2013 [3,4]. 
In contrast, the 2016 the European guideline on CV risk preven-
tion advised against its use for CV risk assessment in the general 
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A B S T R AC T
Background: Our aim was to study the predictive power of integrated central blood pressure-aortic stiffness (ICPS) risk 
categories on cardiovascular (CV) mortality in end-stage renal disease (ESRD) patients. 
Methods: This is a secondary analysis of a prospective study of 91 ESRD patients on hemodialysis therapy. At baseline, pulse 
wave velocity (PWV), central systolic blood pressure (cSBP) and central pulse pressure (cPP) were measured and patients were 
followed up for CV mortality for a median 29.5 months. Based on the shape of the association of each individual ICPS parameter 
with the CV outcome, patients were assigned ICPS scores: one point was given, if either the cSBP value was in the 3rd, or if the 
PWV or cPP was in the 2nd or 3rd tertiles (ICPS range: 0–3). We then evaluated the role of ICPS risk categories (average: 0–1, 
high: 2, very high: 3 points) in the prediction of CV outcomes using Cox proportional hazard regression analysis and compared 
its discrimination (Harrell’s C) to that of each of its components.
Results: We found a strong dose–response association between ICPS risk categories and CV outcome (high risk HR = 2.62, 95% 
CI: 0.82–8.43, p for trend = 0.106; very high risk HR = 10.03, 95% CI: 1.67–60.42, p = 0.02) even after adjustment for multiple 
potential confounders. ICPS risk categories had a modest discrimination (C: 0.622, 95% CI: 0.525–0.719) that was significantly 
better than that of cSBP (dC: 0.061, 95% CI: 0.006–0.117).
Conclusion: The ICPS risk categories may improve the identification of ESRD patients with high CV mortality risk.
H I G H L I G H T S
· Integrated evaluation of central blood pressure and stiffness (ICPS) may improve risk prediction.
· ICPS risk categories were developed and tested in end-stage renal disease (ESRD).
· Very high ICPS risk category is a strong predictor of cardiovascular mortality in ESRD.
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population [5] and in the most recent European hypertension 
guideline the level of recommendation was downgraded to IIb [6]. 
Given these ups and downs, it seems that the scientific audience is 
currently less convinced about the usefulness of the measurement 
of arterial stiffness for CV risk stratification compared to the begin-
ning of the century.
Arterial stiffness can be measured by several methods [7,8]. With 
most of the available devices parallel with the measurement of 
PWV, other parameters can also be evaluated, which correlate with 
PWV and each other, but also reflect on different features of the 
vasculature. Such parameters are the central systolic blood pressure 
(cSBP) reflecting on pressure; central pulse pressure (cPP) reflect-
ing on pulsatility; and augmentation index (AIx) reflecting on 
wave reflection. Recently, we developed an integrated central blood 
pressure-aortic stiffness (ICPS) risk score and based on it defined 
three ICPS risk categories in CKD patients on conservative therapy. 
ICPS risk categories were very strong predictors of CV outcome in 
CKD patients showing superiority over PWV [9].
In the present study our aim was to test the association between 
ICPS risk score and ICPS risk categories and CV mortality in a 
cohort of ESRD patients on HD therapy. We hypothesized that 
ICPS risk categories would be similarly good predictors of CV out-
come in ESRD patients on HD therapy as it was found in CKD 
patients on conservative therapy.
2. MATERIALS AND METHODS
2.1. Participants and Setting
The details of the methods of this retrospective cohort study were 
published previously [10–13]. In brief, patients were recruited 
among ambulatory, chronic (>3 months on HD) ESRD patients of 
two HD units of a dialysis network. None of the patients were hos-
pitalized at the time of baseline investigations. Patients with atrial 
fibrillation were excluded, but otherwise all those patients, who 
gave written informed consent for participation, were included. 
Patients were considered to have established CV disease if they had 
a documented history of myocardial infarction, revascularization 
procedure, stroke or peripheral artery disease. After baseline clin-
ical, laboratory, arterial stiffness and central hemodynamic mea-
surements, patients were followed for a median of 29.5 months 
(interquartile range: 1–51). Follow-up data were collected between 
March 2005 and June 2009. All endpoint information was veri-
fied by original chart review. Outcome measure was death from a 
CV event, which was defined as documented myocardial infarc-
tion, stroke, heart failure, malignant arrythmia leading to death 
or sudden cardiac death. The protocol was approved by the Ethics 
Committee of the dialysis network and was carried out in accor-
dance with the tenets of the Declaration of Helsinki.
2.2.  Arterial Stiffness, Central Hemodynamic 
and Blood Pressure Measurements
All measurements were performed before a midweek HD session, 
with the patient in the supine position in a temperature-controlled 
room (24 ± 1°C). Arterial stiffness measurements and predialysis 
blood sampling were done on separate days within a week.
PWV, AIx, cSBP and cPP were measured by applanation tonometry 
(PulsePen device; DiaTecne s.r.l. Milan, Italy [14]) using sequential 
recordings of the arterial pressure wave at the carotid and femoral 
arteries, and by measurement of the distance between the carotid 
and the femoral sampling sites. Since current recommendation 
suggests the use of 80% of the direct carotid-femoral distance as the 
most accurate proxy of the numerator for PWV measurement, our 
previous data were recalculated accordingly [15].
All the measured parameters were calculated using the PulsePen 
software [14]. PWV was defined as the ratio of the distance and 
the transit time of the pulse pressure wave along the aorta between 
the sampling sites. Pulse wave amplitude was calibrated to brachial 
mean and diastolic pressure measured immediately prior to each 
sequence of pulse wave capture at the two sites. Recordings with 
a systolic or diastolic variability of consecutive waveforms above 
10% or with the amplitude of the pulse wave signal being <80 mV 
were discarded. All measurements were done three times and their 
average was used in the calculations. cSBP was calculated directly 
from the carotid pulse waveform using the calibration considering 
brachial systolic and diastolic blood pressures. cPP was calculated 
as the difference between the highest central systolic and diastolic 
blood pressure values recorded at the carotid sampling site. AIx was 
measured by automatic identification of the ‘1st shoulder’ (inflex-
ion point) on the averaged carotid pulse signal by the PulsePen 
software. The pressure amplitude following this point divided by 
the pulse pressure provided the AIx.
Blood pressure and heart rate were recorded in supine position 
after each arterial stiffness measurement with a validated BpTru 
device (VSM Medtech, Vancouver, Canada). The two sequential 
measurements were manually averaged.
2.3. ICPS Score and Risk Categories
To calculate the ICPS score one point was given, if a patient’s cSBP 
was in the 3rd tertile and if PWV or if cPP were in the 2nd or 3rd 
tertiles. The ICPS score was derived by summing these points 
(range: 0–3 points).
Given the limited statistical power of our relatively small sample 
size, the number of risk categories was further reduced and patients 
were classified into three ICPS risk categories: average (0–1 points), 
high (2 points) or very high (3 points).
2.4. Epidemiologic and Laboratory Data
Baseline data on current smoking, type and presence of diabetes 
mellitus, hypertension, coronary artery disease (previous acute 
myocardial infarction or coronary intervention), chronic heart fail-
ure (clinical diagnosis), peripheral arterial disease (documented by 
angiography or intervention) and cerebrovascular disease (previ-
ous stroke or transient ischemic attack) were collected by health 
record review. Patients were considered to have established CV 
disease if they had a documented history of myocardial infarction, 
revascularization procedure, stroke or peripheral arterial disease.
Blood samples for the determination of blood cell counts and 
hemoglobin, serum cholesterol, triglyceride, LDL-cholesterol, ions, 
albumin, parathormone and 25-OH vitamin D were collected at 
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baseline. Routine blood chemistry measurements were done on a 
Hitachi auto-analyzer, (Japan Care Co. Ltd., Osaka, Japan).
2.5. Statistical Analysis
All data analyses were performed using SPSS 22 for Windows (IBM 
Ltd., USA) or Stata version 13.1 (StataCorp LLC, USA). Continuous 
data are given as mean and standard deviation, or in case of evi-
dence against a normal distribution, as a median and interquar-
tile range. In general, the flow of statistical analysis followed our 
previous report [9].
Arterial stiffness and central hemodynamic parameters were ana-
lyzed both as continuous and categorical variables. For the former, 
these variables were transformed into z-scores to improve their 
comparability and thus the associations are given for one SD dif-
ferences in PWV, AIx, cSBP and cPP for the CV outcome (Cox 
regression). Model 1 was unadjusted, while Model 2 was adjusted 
for age, sex, brachial SBP, LDL-cholesterol, current smoking, diabe-
tes, body mass index and history of CV disease.
Survival was investigated with Kaplan–Meier and Cox regression 
analyses with ICPS score as the predictor and CV mortality as out-
come. The predictive role of ICPS risk categories were investigated 
in Kaplan–Meier curves and Cox regressions with adjustment for 
age, sex, brachial SBP, LDL-cholesterol, current smoking, diabetes, 
body mass index and cardiovascular disease.
Finally, to compare the predictive value of the ICPS risk categories 
and each of its components (PWV, cSBP and cPP), all parameters 
were sequentially entered into a Cox-regression model with CV 
mortality as outcome. To investigate and compare discrimination of 
the different stiffness measures, Harrell’s concordance (Harrell’s C)- 
statistics were calculated.
3. RESULTS
Altogether 126 chronic HD patients at the two dialysis units were 
invited to participate. Of these, 28 patients declined participation 
and seven were excluded because of atrial fibrillation leaving 91 
patients for the analytical sample.
Table 1 displays baseline characteristics including dialysis duration, 
concomitant diseases, traditional CV risk factors, primary renal 
disease leading to ESRD, laboratory and hemodynamic parameters.
Eighty-two patients received antihypertensive medication (case 
numbers in parentheses): renin-angiotensin system inhibitors 
(n = 51), calcium channel blockers (n = 58), b-receptor blockers 
(n = 56), a-receptor blockers (n = 28), and centrally acting antihy-
pertensive drugs (n = 20), either alone or in combination.
In all, n = 58 patients received vitamin D and n = 72 needed cal-
cium carbonate phosphate binder therapy.
During follow-up, 31 cardiovascular deaths were recorded: seven 
patients died from myocardial infarction, seven from sudden car-
diac death, three from arrythmia, eight from heart failure and six 
from stroke.
Table 2 demonstrates the association of PWV, cSBP, cPP and AIx 
(per one SD difference and for each tertile) with CV mortality in 
 unadjusted (Model 1) and in multiply adjusted models (Model 2). As 
a single independent variable, only PWV was significantly related 
to CV mortality. In the analyses by tertiles, the 2nd tertile of PWV 
in Model 1 and the 2nd and the 3rd tertiles of cSBP in Model 2 
were related to the outcome. Unadjusted associations are shown 
as Kaplan–Meyer curves for each tertile of all four parameters 
in Figure 1. It demonstrates non-linear associations: showing an 
increase in the 2nd and 3rd teritle of PWV and cPP and only in the 
3rd tertile of cSBP. As AIx tertiles were not related to outcome and 
the tertile curves crossed each other, this parameter was omitted 
from the ICPS score calculation.
Table 3 demonstrates hazard ratios for CV mortality by ICPS scores 
and risk categories. The risk categories were based on the results of 
the Cox-models (Table 3) and the Kaplan–Meier (Figure 2A) curves 
by collapsing ICPS scores with similar hazard ratios to improve 
Table 1 | Baseline demographic, clinical, laboratory and hemodynamic 
characteristics of participants 
Subjects, n 91
Sex (male, %) 56 (61.5)
Age (years) 63.3 (14.8)
Dialysis duration (months) 29.5 (13.7–33.6)
Residual dialysis (ml/day) 650 (100–1300)
BMI (kg/m2) 25.2 (4.5)
Smoking, n (%) 17 (18.7)
Diabetes, n (%) 38 (41.6)
CV disease, n (%) 55 (60.4)






Other or unknown 10 (11.0)
Laboratory results
Haemoglobin (g/l) 116.0 (103.0–123.0)
Creatinine (µmol/l) 650.0 (516.0–834.0)
Blood urea nitrogen (mmol/l) 19.6 (16–24.5)
Cholesterol (mmol/l) 4.5 (1.2)
HDL-cholesterol (mmol/l) 1.2 (1.0–1.6)
LDL-cholesterol (mmol/l) 2.5 (1.9–3.2)
Triglyceride (mmol/l) 1.7 (1.0–2.7)
Sodium (mmol/l) 137.0 (135.0–139.0)
Potassium (mmol/l) 5.2 (0.9)
Calcium (mmol/l) 2.3 (2.2–2.4)
Phosphate (mmol/l) 1.6 (1.1–1.9)
Albumin (g/l) 40.0 (37.6–42.0)
Parathormone (pmol/l) 7.08 (3.88–18.5)
25-OH vitamin D (µg/l) 24.7 (18.7–36.5)
CRP (mg/l) 6.7 (4.1–15.1)
Hemodynamic data
Systolic blood pressure (mmHg) 141.6 (24.7)
Diastolic blood pressure (mmHg) 77.9 (13.0)
Heart rate (1/min) 72.4 (12.6)
Pulse pressure (mmHg) 62.5 (47.0–79.5)
PWV (m/s) 11.1 (9.3–14.1)
Central SBP (mmHg) 141.9 (23.3)
Central PP (mmHg) 63.5 (47.0–79.0)
AIx (%) 19.0 (11.0–28.5)
Categorical parameters are presented as n, numbers can be also considered as percentage. 
Continuous data are presented as mean (SD) or median (interquartile range). AIx: aug-
mentation index; BMI: body mass index; central PP: central pulse pressure; central  
SBP: central systolic blood pressure; PWV: carotid-femoral pulse wave velocity.
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Table 2 | Cox models with cardiovascular mortality as outcome and individual arterial stiffness and central hemodynamic parameters as predictors 
Variable
Model 1 Model 2
Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value
PWV (per 1 SD) 1.965 1.322 2.920 0.001 1.614 1.069 2.438 0.023
cSBP (per 1 SD) 1.223 0.832 1.798 0.305 1.162 0.787 1.716 0.450
cPP (per 1 SD) 1.345 0.942 1.920 0.102 1.066 0.730 1.556 0.740
AIx (per 1 SD) 0.967 0.677 1.381 0.854 1.431 0.929 2.203 0.104
Variable Tertile N Range Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value
PWV 1st 30 4.7–9.7 1 (ref.) 1 (ref.)
2nd 31 9.7–12.8 0.339 0.122 0.943 0.038 0.527 0.186 1.49 0.227
3rd 30 13.3–24.8 0.951 0.439 2.057 0.898 0.913 0.421 1.98 0.818
cSBP 1st 30 88.3–131.8 1 (ref.) 1 (ref.)
2nd 31 132.5–152 0.540 0.226 1.287 0.164 0.066 0.009 0.502 0.009
3rd 30 154–200.3 0.524 0.227 1.213 0.131 0.141 0.04 0.494 0.002
cPP 1st 30 24–52.3 1 (ref.) 1 (ref.)
2nd 31 52.5–73.3 0.567 0.226 1.421 0.226 0.936 0.365 2.399 0.89
3rd 30 73.5–114.5 0.859 0.384 1.923 0.712 0.982 0.44 2.193 0.964
AIx 1st 31 −0.5–14.5 1 (ref.) 1 (ref.)
2nd 30 15.5–23.0 1.020 0.449 2.315 0.963 0.449 0.179 1.122 0.087
3rd 30 23.5–53.5 0.742 0.298 1.848 0.522 0.445 0.175 1.13 0.089
Model 1 is unadjusted, Model 2 is adjusted for age, sex, current smoking, diabetes, body mass index, cardiovascular disease, brachial systolic blood pressure and LDL-cholesterol. PWV: 
pulse wave velocity; cSBP: central systolic blood pressure; cPP: central pulse pressure; AIx: augmentation index; SD: standard deviation.
Figure 1 | Kaplan–Meier survival curves with cardiovascular mortality as outcome for each integrated central blood pressure-aortic stiffness risk score 
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Table 4 | Harell’s C-statistics for ICPS risk categories and arterial stiffness 
measures and the differences in the C-statistics between ICPS risk 
categories and arterial stiffness measures 
Variable Coefficient Standard error 95% CI p-value
ICPS risk categories 0.622 0.049 0.525 0.719 <0.001
PWV 0.662 0.052 0.558 0.766 <0.001
cSBP 0.561 0.052 0.456 0.665 <0.001
cPP 0.588 0.05 0.489 0.687 <0.001
ICPS risk categories 
vs. PWV
−0.04 0.051 −0.142 0.062 0.438
ICPS risk categories 
vs. cSBP
0.061 0.028 0.006 0.117 0.031
ICPS risk categories 
vs. cPP
0.034 0.028 −0.022 0.089 0.226
Bold values demonstrate significance when p < 0.05. CI: confidence intervals; ICPS risk 
categories: integrated central pressure-stiffness risk categories; PWV: carotid-femoral 
pulse wave velocity; cSBP: central systolic blood pressure; cPP: central pulse pressure.
Table 3 | The relation of integrated central blood pressure-aortic stiffness 
(ICPS) risk score and ICPS risk categories with cardiovascular mortality 
based on Cox proportional hazard regression models 
N Hazard ratio 95% CI p-value
ICPS risk score
Model 1
0 point 18 1 (ref.)
1 point 17 1.463 0.327 6.543 0.781
2 points 33 2.323 0.654 8.246 0.869
3 points 23 3.552 1.001 12.598 0.297
Model 2
0 point 18 1 (ref.)
1 point 17 0.668 0.131 3.399 0.627
2 points 33 2.112 0.410 10.886 0.371
3 points 23 10.126 1.056 97.110 0.045
ICPS risk categories
Model 1
Average 35 1 (ref.)
High 33 1.902 0.748 4.837 0.177
Very high 23 2.910 1.145 7.396 0.025
Model 2
Average 35 1 (ref.)
High 33 2.622 0.816 8.432 0.106
Very high 23 10.034 1.666 60.425 0.012
Model 1 was unadjusted, while Model 2 was adjusted for age, sex, brachial systolic blood 
pressure, LDL-cholesterol, current smoking, diabetes, body mass index and CV disease.
 statistical power. Almost two-third participants were classified 
into the high and very high-risk categories. Kaplan–Meier survival 
curves for the three ICPS risk categories are shown in Figure 2B.
Table 3 shows that participants in the very high ICPS risk category 
had a substantially increased CV mortality risk and also a stepwise 
increase from average through high to very high risk after adjust-
ment for multiple CV risk factors. In Model 2, besides the very high 
ICPS risk category older age (HR: 1.05, 95% CI: 1.01–1.09) and 
lower systemic systolic blood pressure (HR: 0.97, 95% CI: 0.94–
1.00) remained independent predictors of CV mortality.
Table 4 shows C-statistics (and differences between C-statistics) for 
ICPS risk categories and PWV, cSBP, and cPP. All C-values show 
moderate discrimination, however discrimination by ICPS risk cat-
egories was superior to that of cSBP. A tendency may also be seen 
in the case of cPP, while ICPS risk categories and PWV had similar 
C-statistics.
4. DISCUSSION
Our study demonstrated that integrated risk categories based on 
arterial stiffness and central hemodynamic parameters (ICPS) 
are related to cardiovascular mortality not only in conservatively 
Figure 2 | Kaplan–Meier survival curves for the integrated central blood pressure-aortic stiffness (ICPS) risk scores and ICPS risk categories for 
cardiovascular mortality as outcome. Panel A: ICPS risk score groups; Panel B: ICPS risk categories.
A B
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treated CKD patients but also in ESRD patients on HD therapy. 
According to our results, people in the very high ICPS risk category 
have a remarkably elevated risk of CV mortality, while patients in 
the high risk category have intermediate risk. ICPS risk categories 
had a better discriminative ability for CV mortality than cSBP by 
itself, had a numerically higher C-statistics that cPP and similar 
discrimination to that of PWV.
Recently, we introduced an ICPS risk score and derived three ICPS 
risk categories based on it, there were strong predictors of CV 
events in CKD patients on conservative therapy [9]. In that cohort 
participants in the high ICPS risk category had a significantly ele-
vated CV risk compared with the average risk group. We believe 
this is due to the limited power of the present study as the number 
of events during the follow-up was lower in the ESRD compared 
with the CKD cohort (n = 31 vs. n = 49) [9].
In our CKD cohort the ICPS risk categories showed superior dis-
crimination over PWV in the prediction of CV events [9], while 
it was similar in the present ESRD cohort. This is probably due to 
the fact, that PWV is a much stronger predictor of CV outcomes 
in ESRD patients on HD compared with that in CKD patients on 
conservative therapy [2]. This latter hypothesis is supported by 
our previous report on the CKD cohort [16]. This phenomenon 
is probably due to the accelerated vascular calcification in dialysis 
patients, which is strongly associated with mineral-bone disorder 
[17] and eventuates in elevated arterial stiffness and PWV.
As we highlighted in our previous manuscript, there are multiple 
potential advantages of the ICPS score concept over the use of its 
individual components. The required parameters can easily be esti-
mated with most of the commercially available devices, its determi-
nation is non-invasive as it requires no blood sampling and it also 
can bridge the divergent methodologies [9]. A recently published 
study also supports our concept. Niiranen et al. [18] assessed the 
prognostic value of the joint evaluation of central pulse pressure 
and carotid-femoral pulse wave velocity by dividing the population 
into high and low risk groups based on the categorization of the 
medians of these values in the Framingham Heart Study. They have 
found, that patients in “high/high” group had a 52% higher risk of 
CV events compared with the low/low group [18]. Unfortunately 
in this study the discriminative ability of this simple categorization 
was not compared with that of its components.
As the present definition of ICPS risk categories is based on a lim-
ited sample, we do not recommend its calculation using the cut-
off values from our sample in the general population, not even in 
ESRD patients on hemodialysis. A valid risk score should be based 
on much larger samples with an adequate number of CV events 
that enables the investigation of each parameter involved in the 
score [19]. However, as our ICPS risk categories in the present sim-
plified form are strong predictors of CV mortality in our cohort, we 
believe that our pilot report could generate important discussion 
and further studies.
There are some limitations of our study that has to be acknowl-
edged. As patients with atrial fibrillation are ineligible for tonomet-
ric arterial stiffness measurements, they were excluded from the 
present analysis, the ICPS score cannot be calculated for a substan-
tial proportion of ESRD patients. Due to the low number of partic-
ipants and events, our study is underpowered and thus the exact 
thresholds used for scoring or the relative contribution of each 
components cannot be exactly defined. Given these limitations, 
our aim with the present report is not to define the final score but 
to introduce the concept of a combined risk score based on arterial 
stiffness and central hemodynamic parameters and highlight some 
of its potential advantages.
In conclusion, our integrated score and the ICPS risk categories 
derived from it showed a strong association with CV mortality in 
ESRD patients on hemodialysis therapy. Our findings highlight the 
potential for a combined measure of arterial stiffness and central 
hemodynamic parameters for CV prediction. Together with our 
previous results of CKD patients on conservative therapy, this is the 
second independent cohort where our new concept demonstrated 
promising results.
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